The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $271,697 Project Grant to The Johns Hopkins University on Sep 1, 2024. The grant funds research to "TARGET GUT BACTERIAL ANDROGEN PRODUCTION TO REVERSE ABIRATERONE RESISTANCE IN METASTATIC PROSTATE CANCER". This research aims to develop new treatments for metastatic prostate cancer by investigating the role of gut bacteria in androgen production and resistance to certain cancer...
The Johns Hopkins University will provide research services totaling $1,216,646 under a Project Grant award from the Defense Health Agency. The award's stated purpose is to investigate the role of polyamine metabolism in advanced prostate cancer. The grant falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care. Specifically, the program aims to develop medical solutions for battlefield...
This $1,473,751 federal Project Grant award, issued on August 15, 2024 by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports research by The Johns Hopkins University to investigate the influence of the tumor immune microenvironment and microbiome on prostate cancer immunotherapy response in Black men. The 3-year research initiative aims to transform healthcare through innovative and impactful medical research focused...
This federal Project Grant award, ID HT94252410076, was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to The Johns Hopkins University. The $163,750 award, granted on February 1, 2024, will support research examining the influence of the gut microbiome on drug metabolism and treatment resistance in prostate cancer, with a completion date of January 31, 2026. As a leading research institution, The Johns Hopkins...
This $459,932 federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) will fund research by The Johns Hopkins University to investigate mechanisms of prostate cancer aggressiveness and metastasis. The research aims to uncover new insights into cribriform lesions, a potentially aggressive form of prostate cancer. This 2-year award from June 2025 to May 2027 will support the university's expert biomedical...
This $232,878 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by The Johns Hopkins University to explore the role of epitranscriptomics in the evolution of neuroendocrine prostate cancer. The award, with a performance period from June 1, 2025 to May 31, 2027, will fund advanced biomedical research investigating innovative approaches to disease prevention, diagnosis, treatment, and...
This $484,013 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of "PSMA-TARGETED MULTIPARAMETRIC ULTRASOUND" research at The Johns Hopkins University. The award period runs from August 1, 2024 to July 31, 2026. The project aims to advance biomedical research and innovative medical solutions relevant to military personnel and the broader public. As a leading research institution, The...
This $1,406,799 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research to develop real-time localization techniques using near-infrared fluorophores to guide robotic-assisted radical prostatectomy procedures. The 3-year award, running from August 1, 2024 to July 31, 2027, will enable Johns Hopkins to conduct innovative biomedical research to improve surgical outcomes and...
The Johns Hopkins University was awarded a $1,228,125 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research titled "PSMA-TARGETED ACTIVATED MYELOID CELLS AS A NOVEL PROSTATE CANCER IMMUNOTHERAPY" from September 2021 through September 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
This $867,712 Project Grant award from the Department of the Army Medical Command (under the Military Medical Research and Development program, CFDA 12.420) supports advanced biomedical research at The Johns Hopkins University focused on transforming healthcare for military service members and the general public. The research aims to investigate effective treatment of pancreatic cancer through systemic chemotherapy combined with alpha-particle radiotherapy, with a focus on early hepatic...